Notable portfolio companies include Aadi Bioscience, Fore Biotherapeutics, Gain Therapeutics, Geneos Therapeutics, MEI Pharma, On Target Laboratories, OncoResponse, and Personal Genome Diagnostics. The fund is guided by a mission to build on innovation and is driven by core values centered around patient needs and scientific passion. 3B Future Health Fund offers unique value-add services through its deep industry expertise and extensive network, helping portfolio companies navigate the complex landscape of healthcare innovation.
3B Future Health Fund - Portfolio Snapshot
Portfolio activity breakdown across disclosed investments and stages
Portfolio Companies9
Follow-on Investments9
Current Portfolio Count8
Total Portfolio Exits1
Top Investment Stages
Series A5 (33.3%)
Series B4 (26.7%)
Series D3 (20.0%)
Series C2 (13.3%)
3B Future Health Fund
3B Future Health Fund, a Luxembourg-based investment firm, focuses on early-stage investments in innovative companies addressing high unmet patient needs, particularly in the rare disease and oncology sectors. The fund primarily supports US and European-based private companies and typically participates in Seed, Series A, B, C, and D rounds. Their investment strategy emphasizes leveraging scientific expertise and a robust network to discover and develop life-changing therapies.
Seed1 (6.7%)
Stage Mix
Series A 33%Series B 27%Series D 20%Series C 13%Seed 7%
Concentration shown as share of disclosed investments by stage.
